Abstract
The combined impact of immunity and SARS-CoV-2 variants on viral kinetics during infections has been unclear. To address this gap, we characterized 2,964 infections in the National Basketball Association occupational health cohort. Over half remained potentially infectious (cycle threshold (Ct)<30) five days post detection, with minimal differences by variant and vaccination history. Only 7/1032 infections (0.7%) showed viral rebound, defined as 3+ days with Ct<30 following an initial clearance of 3+ days with Ct≥30. Pre-booster antibody titers and symptoms predicted peak viral RNA and clearance rates. Boosted individuals with Omicron BA.1 infections were more likely to have low pre-booster antibody titers and cleared their infections more slowly than non-boosted individuals. Since booster vaccination protects against infection, these longer clearance times suggest viral clearance takes longer in individuals with less infection protection. The shifting landscape of viral kinetics underscores the need for continued monitoring to optimize clinical and public health interventions.
Competing Interest Statement
CM, CGT, RMS and SC are employees of IQVIA, Real World Solutions. DJA is co-owner of Infection Control Education for Major Sports, LLC. GK, MM, MP, SK, AM, IE, DS, TB, BH, JTD and CEM are employees of TEMPUS labs. NDG and JRF have a consulting agreement for Tempus and receive financial support from Tempus to develop SARS-CoV-2 diagnostic tests. SMK and YHG have a consulting agreement with the NBA.
Funding Statement
Supported in part by CDC contract 200-2016-91779, Emergent Ventures at the Mercatus Center, the Huffman Family Donor Advised Fund, the MorrisSinger Fund, the National Basketball Association, and the National Basketball Players Association.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Residual de-identified viral transport media from anterior nares and oropharyngeal swabs collected from players, staff, vendors, and associated household members from a professional sports league were obtained from BioReference Laboratories. In accordance with the guidelines of the Yale Human Investigations Committee, this work with de-identified samples was approved for research not involving human subjects by the Yale Institutional Review Board (HIC protocol # 2000028599). This project was designated exempt by the Harvard Institutional Review Board (IRB20-1407).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** Co-senior authors.
Funding Statement: Supported in part by CDC contract 200-2016-91779, Emergent Ventures at the Mercatus Center, the Huffman Family Donor Advised Fund, the MorrisSinger Fund, the National Basketball Association, and the National Basketball Players Association.
Data availability: All code and data required to reproduce the analyses are available at https://github.com/gradlab/SC2-kinetics-immune-history.
Substantial update of results, data and text. New analyses including information on rebound infections, immune history and symptom status.
Data Availability
Code and data to regenerate these analyses, including individual cycle threshold value trajectories, are available at https://github.com/gradlab/SC2-kinetics-immune-history.
